Ovid Therapeutics and Angelini Pharma S.p.A. have entered an agreement in which Angelini Pharma will develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the EU and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia. Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG. OV101 is believed to be the only delta (δ)-selective GABAA receptor agoni...